This article needs to be updated.(November 2021)
|Date||17 February 2021 – present|
|Cause||COVID-19 pandemic in Japan|
|Target||Full immunisation of people in Japan against COVID-19|
|Organised by||Ministry of Health, Labour and Welfare|
|Participants||77,098,247 people have received at least one vaccine dose|
(7 September 2021)
61,995,078 have been fully vaccinated (received both vaccine doses, 7 September 2021)
|Outcome||49.4% of the Japanese population has received their first dose of a two-dose vaccine|
39.1% has been fully vaccinated
|Website||Novel Coronavirus (COVID-19) information|
COVID-19 vaccination in Japan started later than in most other major economies.The country has frequently been regarded "slow" for its vaccination efforts.
Japan has so far approved Pfizer–BioNTech, Moderna and Oxford–AstraZeneca for use. As of mid-August 2021, around 46 million [ citation needed ] people have been fully vaccinated in the country.
On 14 February 2021, Pfizer was approved by the government of Japan,and was deployed on 17 February 2021. On 28 May 2021, Pfizer was approved by the Japanese health ministry panel for adolescents aged between 12 and 15 years.
On 21 May 2021, Moderna and Astrazeneca were approved by the government of Japan.
|Pfizer–BioNTech||14 February 2021||17 February 2021||194|
|Moderna||21 May 2021||23 May 2021||100|
|Oxford–AstraZeneca||21 May 2021||16 August 2021||120|
Note: Japan has donated 1.24 million doses of AstraZeneca vaccine to Taiwan and 1 million doses to Vietnam. There are plans to send additional 2 million doses to these countries. Japan has also donated 1 million doses each to Thailand, Malaysia, Indonesia and the Philippines.Japan also donates over 2 million doses of AstraZeneca Vaccine to Iran through COVAX.
|Vaccine||Country of origin||Type (technology)||Progress||Ref|
| AG0302-COVID‑19 |
AnGes Inc., AMED
|Japan||DNA vaccine (plasmid)||Phase II–III (500)|
Randomized, double-blind, placebo controlled
Nov 2020 –Apr 2021, Japan
|Japan||Subunit||Phase I–II (214)|
Randomized, double-blind, placebo-controlled, parallel-group.
Dec 2020 –Jun 2022, Japan
|Japan||RNA||Phase I–II (152)|
A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects.
Mar 2021 –Jul 2022, Japan
KM Biologics Co
|Japan||Inactivated SARS‑CoV‑2||Phase I–II (210)|
Randomized, double blind, placebo control, parallel group.
Mar 2021 – Dec 2022, Japan
Elixirgen Therapeutics, Fujita Health University
|Japan, United States||RNA||Phase I–II (60)|
First in Human, randomized, placebo-controlled.
Apr 2021 –Jan 2023, Japan
In April 2021, prime minister Suga Yoshihide announced that Japan will receive 50-million doses of the Pfizer vaccine after a meeting with the company's CEO.
The roll out of the vaccines in Japan, with 4 percent of the population inoculated as of May 21, 2021, has led to criticisms on slow approval, disruptions on import, and the lack of medical professionals.A poll conducted in April showed that more than 60 percent of people were dissatisfied with Japan’s vaccine rollout, with experts stating that it was too late now to stop the spread of variants with vaccines.
This section is empty. You can help by adding to it. (May 2021)
This section is empty. You can help by adding to it. (May 2021)
The Therapeutic Goods Administration (TGA) is the medicine and therapeutic regulatory agency of the Australian Government. As part of the Department of Health, the TGA regulates the quality, supply and advertising of medicines, pathology devices, medical devices, blood products and most other therapeutics. Any items that claim to have a therapeutic effect, are involved in the administration of medication, or are otherwise covered by the Therapeutic Goods Act 1989, the Therapeutic Goods Regulations 1990, or a ministerial order, must be approved by the TGA and registered in the Australian Register of Therapeutic Goods.
The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.
The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.
The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, and will continue with the goal of vaccinating all willing Australians before 2022. Front-line workers and aged care staff and residents will be the first Australians to be inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine is not included in the Australian vaccination program.
The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.
COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020 and is currently ongoing.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination programs have begun in many countries and territories in Africa. As of 5 July 2021, vaccination campaigns had started in 51 African countries with 36.5 million people receiving at least one dose.
The National Advisory Committee on Immunization is an advisory body that provides the Government of Canada with medical and scientific advice relating to human immunization.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks fifth in the world and second in Asia.
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.
Nepal began administration of COVID-19 vaccines on 27 January 2021. 1 million Oxford-Astrazeneca vaccines were provided by India as a grant while Nepal brought 2 million doses from Serum Institute of India (SII) and was one of the first to receive COVID-19 vaccines. The delivery of the first 1 million doses arrived on 21 February. In March, India's decision to ban exports of vaccines created uncertainty over whether Nepal would be able to continue its vaccinations. By April, SII had only provided half of the 2 million doses for which Nepal had paid in full. A spokesperson for the Indian Ministry of External Affairs rejected the notion of an export ban and said “We will export vaccines taking into account the domestic demand.” By late July, there was still uncertainty in Nepal over when SII would deliver the vaccines that were purchased, although Prime Minister Narendra Modi said India would "resume the supply of vaccines soon."
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 18 March 2021, vaccinations commenced on 22 March 2021, and will continue throughout the year with the goal of vaccinating 70% of the population by late October 2021.
COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.